{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:32:07Z","timestamp":1791649927972,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cllc.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T22:13:24Z","timestamp":1647468804000},"page":"320-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management"],"prefix":"10.1016","volume":"23","author":[{"given":"Remi","family":"Veillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-8440","authenticated-orcid":false,"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B.","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-7449","authenticated-orcid":false,"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Melosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhit","family":"Baijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto de Castro","family":"Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Sedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.03.002_bib0001","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0002","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2022.03.002_bib0003","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2022.03.002_bib0004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2022.03.002_bib0005","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2020-0760","article-title":"New verse for a familiar song: small molecule inhibitors for MET exon 14 skipping non-small cell lung cancer","volume":"25","author":"Le","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2022.03.002_bib0006","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.002_bib0007","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/1078-0432.CCR-12-3247","article-title":"EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors","volume":"19","author":"Bladt","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-19-2860","article-title":"First-in-man Phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.002_bib0009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cllc.2022.03.002_bib0010","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1016\/j.jtho.2021.01.250","article-title":"MA11.05 - Tepotinib In Patients With MET Exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results From VISION Cohort A","volume":"16","author":"Paik","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from VISION relevant for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.002_bib0012","doi-asserted-by":"crossref","first-page":"S984","DOI":"10.1016\/j.annonc.2021.08.1857","article-title":"1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC","volume":"32","author":"Garassino","year":"2021","journal-title":"Ann Oncol"},{"issue":"S4","key":"10.1016\/j.cllc.2022.03.002_bib0013","doi-asserted-by":"crossref","first-page":"S864","DOI":"10.1016\/j.annonc.2020.08.1661","article-title":"1347P Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib","volume":"31","author":"Garassino","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0014","series-title":"TEPMETKO (tepotinib) Prescribing Information","year":"2021"},{"key":"10.1016\/j.cllc.2022.03.002_bib0015","article-title":"Japan, an affiliate of the healthcare business of Merck KGaA Darmstadt, Germany","year":"2020","journal-title":"TEPMETKO (Tepotinib) Japanese Package Insert"},{"key":"10.1016\/j.cllc.2022.03.002_bib0016","series-title":"Non-Small Cell Lung Cancer Version 4.2021","year":"2021"},{"key":"10.1016\/j.cllc.2022.03.002_bib0017","unstructured":"Japanese Lung Cancer Society. Lung cancer practice guidelines. 2020. Accessed from: https:\/\/www.haigan.gr.jp. Accessed at: May 13, 2021."},{"key":"10.1016\/j.cllc.2022.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non\u2013small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2019.11.010","article-title":"Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer","volume":"140","author":"Pruis","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.03.002_bib0020","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jjco\/hyaa042","article-title":"Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors","volume":"50","author":"Shitara","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0021","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41416-021-01334-9","article-title":"Phase 1b\/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression","volume":"125","author":"Decaens","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2022.03.002_bib0022","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41416-021-01380-3","article-title":"Randomised Phase 1b\/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression","volume":"125","author":"Ryoo","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2022.03.002_bib0023","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/psp4.12602","article-title":"Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose","volume":"10","author":"Xiong","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2022.03.002_bib0025","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.03.002_bib0026","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.18632\/oncotarget.2003","article-title":"HGF\/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development","volume":"5","author":"Hack","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2022.03.002_bib0027","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ebiom.2015.03.021","article-title":"MET suppresses epithelial VEGFR2 via intracrine VEGF-induced endoplasmic reticulum-associated degradation","volume":"2","author":"Chen","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cllc.2022.03.002_bib0028","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non\u2013small-cell lung cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0029","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1016\/j.annonc.2020.08.698","article-title":"584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours","volume":"31","author":"Paik","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcp.13434","article-title":"Renal function monitoring in heart failure \u2013 what is the optimal frequency? A narrative review","volume":"84","author":"Al-Naher","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cllc.2022.03.002_bib0031","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jtho.2020.10.052","article-title":"MO01.04 Management of selected adverse events with capmatinib: Institutional experiences from the GEOMETRY Mono-1 trial","volume":"16","author":"Goodwin","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0032","series-title":"Center for Drug Evaluation and Research (application number: 214096Orig1s000): Multi-discipline review","year":"2020"},{"key":"10.1016\/j.cllc.2022.03.002_bib0033","series-title":"TABRECTA (capmatinib) Prescribing Information","year":"2020"},{"key":"10.1016\/j.cllc.2022.03.002_bib0034","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1038\/s41598-018-27672-y","article-title":"Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1","volume":"8","author":"Omote","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2022.03.002_bib0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2021.04.009","article-title":"Capmatinib-induced pseudo-acute kidney injury: a case report","volume":"79","author":"Mohan","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cllc.2022.03.002_bib0036","first-page":"170","article-title":"Markers of renal function tests","volume":"2","author":"Gowda","year":"2010","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.cllc.2022.03.002_sbref0037","series-title":"Pleural Effusions in Lung Cancer: Detection and Treatment","article-title":"In: Lung Cancer - Strategies for Diagnosis and Treatment","author":"Medenica","year":"2018"},{"key":"10.1016\/j.cllc.2022.03.002_bib0038","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0039","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"issue":"Suppl 7","key":"10.1016\/j.cllc.2022.03.002_bib0040","doi-asserted-by":"crossref","first-page":"S779","DOI":"10.21037\/tcr.2018.08.11","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors","volume":"7","author":"Sehgal","year":"2018","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.002_bib0041","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2022.03.002_bib0042","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","article-title":"ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non\u2013small cell lung cancer (NSCLC)","volume":"12","author":"Cho","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0043","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.21037\/jtd.2018.05.75","article-title":"Lung cancer and interstitial lung disease: a literature review","volume":"10","author":"Naccache","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2022.03.002_bib0044","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.cllc.2022.03.002_bib0045","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.cllc.2022.03.002_bib0046","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.002_bib0047","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/14737140.2016.1170596","article-title":"Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles","volume":"16","author":"Rossi","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cllc.2022.03.002_bib0048","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 13","key":"10.1016\/j.cllc.2022.03.002_bib0049","doi-asserted-by":"crossref","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","article-title":"Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: Focusing on non-small cell lung cancer patients","volume":"10","author":"Remon","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2022.03.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.cllc.2022.03.002_bib0051","article-title":"Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: A clinical review [published online ahead of print, 2022 Feb 4]","volume":"1525-7304","author":"Cortot","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:04Z","timestamp":1761505984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1525730422000389"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.03.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}